Scientists use DNA from three people to protect babies from rare disease
Four girls and four boys, including one set of twins, were born healthy after scientists used the treatment to prevent mothers with mutations in their mitochondrial DNA from transmitting the condition to their children, scientists at Newcastle University in northern England said in a statement Wednesday.
Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post.
The authors say it represents the first study into an entire cohort of babies and paves the way for further research on their health outcomes, as well as improved medical techniques for that specific treatment - which is granted approval in the United Kingdom on a case-by-case basis.
Mitochondria are commonly known as the 'powerhouse of the cell' and produce energy required for major parts of the body to function. However, small mutations in mitochondrial DNA can affect tissues with high-energy demands such as the heart, muscle and brain, causing devastating disease and, in some cases, death.
Mitochondrial DNA is inherited from the mother, and although males can be affected, they do not transmit the disease, researchers said. About 1 in 5,000 babies are born worldwide each year with mutations that can cause the disease, researchers said.
Now, scientists have detailed how an IVF technique called pronuclear transfer has been used to combine the DNA of three people to reduce the risk of mitochondrial disease being passed down the generations, in accompanying studies published in the New England Journal of Medicine on Wednesday.
The technique uses 99.9 percent of the DNA from a man and woman, with another 0.1 percent from a second woman's donor egg. It works by transplanting the nuclear genome of an egg from the mother with the condition - which contains genes essential for individual characteristics like hair color and height - to an egg donated by an unaffected woman that has had its nuclear genome removed, researchers said.
The resulting embryo inherits nuclear DNA from its two parents, but the mitochondrial DNA comes from the donated egg, researchers said. The treatment was offered to certain women at very high risk of passing on serious mitochondrial disease, in accordance with U.K. regulations that assess each application for the procedure on a case-by-case basis.
The eight infants - who range in age from newborn to over 2 years old - were assessed to be healthy, meeting developmental milestones and reported levels of mitochondrial disease-causing mutations that were undetectable or at levels unlikely to cause disease, the Newcastle University statement said. Three of the babies had levels of disease-causing mitochondrial DNA mutations of up to 20 percent, which is still below the 80 percent threshold for clinical disease, it added.
Doug Turnbull, a neurologist at Newcastle University who co-wrote the study, said it was the first to document a 'cohort' of children who had received the treatment. He said it is the result of an extremely cautious approach by scientists and regulators that has been more than two decades in the making.
'People have used very similar techniques, but nobody's quite used this particular technique,' he told The Washington Post in a phone interview Thursday. 'It's just absolutely critical when you're doing a new technique to be cautious and to make sure … it's as safe and efficient as possible.'
The procedure has also raised concern from some, including religious groups, about its ethics and the fear that it could open the door to further genetic modification.
Peter Thompson, chief executive of the Human Fertilization and Embryology Authority, which regulates the process in Britain, said that only people with a 'very high risk' of passing on a serious mitochondrial disease are eligible for the treatment and that every application is assessed individually. As of July 1, 35 patients have been granted approval by U.K. authorities to proceed with the treatment since it was first licensed in 2017.
'These robust but flexible regulatory processes allow the technique to be used safely for the purposes that Parliament agreed in 2015,' Thompson said in a statement in response to Wednesday's news.
Scientists have cautiously welcomed the findings, while stressing the importance of long-term monitoring and raising the prospect of whether the procedure offers advantages over embryo screening for genetic disease. Others have raised the issue of cost in the long-term project that is supported by Britain's National Health Service and medical charity the Wellcome Trust, among other groups.
Mary Herbert, who is professor of reproductive biology at Newcastle University and lead author of the research paper, said 'the findings give grounds for optimism' but further research is needed to 'bridge the gap' between reducing risk of mitochondrial disease and preventing it.
Turnbull said the team is also looking to improve medical techniques and follow up with the children involved for as long as possible to track their health outcomes. He said researchers are offering health assessments for five years, but it 'would be lovely to be able to follow them up much longer.'
Joanna Poulton, a professor in mitochondrial genetics at the University of Oxford, who was not involved in the research, said 'time will tell' whether the treatment results in 'dramatic clinical advance.'
The births come amid a wider boom in genomic sequencing and IVF start-ups that have sparked a wider debate about the ethics and science behind embryo screening and genetic preselection.
In the United States, those undertaking IVF typically test for rare genetic disorders stemming from a single gene mutation, such as cystic fibrosis, or chromosomal abnormalities such as Down syndrome. The use of donor mitochondria, however, is not permitted under U.S. regulations. In Britain, the creation of babies using DNA from three people was first made legal in 2015, hailed for its ability to prevent serious disease being passed on.
Related Content
Democrats try a new tone: Less scripted, more cursing, Trumpier insults
An asylum seeker abandons her claim and leaves Trump's America
He may have stopped Trump's would-be assassin. Now he's telling his story.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
John Swinney pays tribute to Scottish woman who lost battle with anorexia aged 20
First Minister John Swinney has paid tribute to a young Scottish constituent who sadly lost her battle with anorexia earlier this year. The first minister attended a charity park run, which was organised by the family of Rachel Bywater from Aberfeldy, to raise funds for BEAT, the UK's leading charity supporting those affected by eating disorders, reports The Record. Swinney joined the family of Rachel, who sadly died on May 17 this year aged just 20 years old, at the event which has raised an amazing £7,500 for the charity. READ MORE: Netflix viewers rush to watch 'compelling' BBC drama series set in Edinburgh READ MORE: Edinburgh's first 'queer cafe' announces closure as owners say 'this is only the beginning' The MSP for Perthshire North shared a snap of the group together sporting their, 'Run for Rachel' t-shirts and wrote: "A special privilege to join the family of Rachel Bywater - one of my constituents who faced an eating disorder and sadly died recently aged only 20 - to run a 5k and raise funds for Beat (Eating Disorders). "Wonderful to see so many in the #Aberfeldy community supporting today." Her father Dave Bywater added: "Thank you John, it was great to have your support and that of the community. 'I hope everyone who reads these posts can realise there is a family behind this who are suffering a tragic loss, and ignore the offensive responses you have received." Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages. Ahead of the event her family wrote: "We will be installing a new bench on the River Bank for Rachel Bywater, who very sadly passed away on May 17th this year. "To mark the occasion a fund raiser will be held on the Sunday to raise funds for BEAT (Eating Disorders). All you have to do is walk, jog or run 1, 2 or 3 laps of the FeldyRoo Fitness Trail. "The choice is yours, all we want is everyone to get involved. You can fill in an entry form and pick up sponsorship form at any of the pubs - Fountain, Black Wach or Schiehallion. "Entry is totally free but raised sponsorship or donations on the day would be really appreciated no matter how little or large."
Yahoo
3 hours ago
- Yahoo
Human Babies Aren't Supposed to Have 3 Parents—but Now They Can
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Here's what you'll learn when you read this story: The first babies with three biological parents were born out of a new technique to prevent mitochondrial disease. The nucleus of an egg fertilized in vitro was transferred into a donor egg without a nucleus, but with viable mitochondria. Eight healthy babies, including a set of twins, were born with low to undetectable levels of mitochondrial mutations. The only creatures known to conceive offspring from more than two parents are salamanders. Females from the genus Ambystoma (which are notoriously promiscuous) mate with up to three different males, and that DNA is then incorporated into what is known as a triploid genome in their offspring. Now a version of this has become possible in humans. It seems limb regeneration isn't the only way medical intervention can put humans on salamanders' level. Being born with three genomes is not a phenomenon that occurs naturally in Homo sapiens, but in an attempt to prevent certain genetic conditions caused by mutations in the mitochondria, scientists have found a way. Mitochondrial DNA or mtDNA is exclusively passed down from the maternal side. Dysfunction in the mitochondria can lead to metabolic diseases characterized by symptoms such as seizures, developmental delays, blindness, and loss of muscular function. Some can even be fatal. Mitochondrial diseases occur in about 1 in every 5,000 people. They were previously only preventable by using a donor egg or foregoing the conception of biological children altogether. This is why pediatric neurologist Bobby McFarland, of Newcastle University in the UK, led an experimental study that would reduce and potentially eliminate the risk of mitochondrial disease with a new method of in vitro fertilization. McFarland and his research team wanted see if removing the nucleus of an egg and placing it in a donor egg with viable mitochondria would result in healthy offspring. 'We found that pronuclear transfer, a form of mitochondrial donation, was effective in reducing the level of pathogenic mtDNA variant to substantially below the threshold for clinical disease in the offspring of women with homoplasmic (or high heteroplasmic) levels,' he said in a study recently published in the New England Journal of Medicine. When mitochondria are homoplasmic, all copies produced by cell division have mutations. Mutation levels vary in heteroplasmic mitochondria. Preimplantation genetic testing (PGT) can screen for these abonormalities, and women with homoplasmy or high levels of heteroplasmy can benefit from what is now known as pronuclear transfer. This involves eggs from both the mother and donor being fertilized with the father's sperm in vitro. Nuclei are then removed from both eggs after ten hours. Since the nucleus carries most genetic material and has no connection to mitochondrial disease, the mother's nucleus is implanted into the donor egg to take advantage of its mitochondria. While there is a chance that a few of the mother's mitochondria may end up in the embryo, it is unlikely to cause a debilitating disease. Levels of defective mitochondria in offspring conceived via pronuclear transfer were low enough to escape that fate. Eight pregnancies (including a set of twins) resulted from the experiment, and while there were a few minor health problems in the newborns, these were either treatable or corrected themselves. Not only were levels of heteroplasty low for the babies, but undetectable in five of them. Developmental progress also turned out to be normal. Though one baby had a form of infant epilepsy, and another had heart arrhythmia and hyperlipidemia, or high levels of fats and lipids in the blood, both of these conditions were treated and resolved. Whether the hyperlipidemia was even caused by mtDNA is uncertain, especially because the mother also had severe hyperlipidemia during her pregnancy. Though there was a chance that any of the mothers with pathogenic mtDNA had a higher risk of complications during pregnancy, which could possibly cause their children to have health issues, there is no proof for now. 'We are assessing, over the long term, the health and extent of heteroplasmy (if detectable) of the offspring,' McFarland and his team said. 'Indeed, the role of mitochondrial donation as a choice for women with a heritable pathogenic mtDNA variant will only be established with the availability of additional data.' You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50 Solve the daily Crossword
Yahoo
3 hours ago
- Yahoo
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten